抗体-药物偶联药物的研究进展  

Research progress of antibody-drug conjugate

作　　者：石依冉 王岩[1] 陈少欣[1] 

机构地区：[1]中国医药工业研究总院上海医药工业研究院,创新药物与制药工艺国家重点实验室,上海200040

出　　处：《世界临床药物》2013年第12期755-759,共5页World Clinical Drug

基　　金：微生物药物技术创新与新药创制产学研联盟(2010ZX09401-403)

摘　　要：抗体-药物偶联物(ADC)也称为免疫偶联物,属于靶向抗肿瘤药物,由药物、抗体以及偶联抗体和药物的连接物所组成。当抗体和肿瘤细胞表面的抗原特异性结合时,抗体-药物偶联物可将药物成功释放到肿瘤细胞特定部位。本文主要概述抗体-药物偶联物的作用机理、分类以及相关药物的临床进展并重点介绍最新上市的药物曲妥珠单抗-美登木素I(T-DM1,Kadcyla)。Antibody-drug conjugate（ADC）, also called immunoconjugates, is a kind of targeted anti-cancer chemotherapeutics. It consists of cytotoxic drug, monoclonal antibody and the linker connecting drug to antibody. The antibody in ADC can specifically bind to the antigen on tumor cell and release the drug to the specific site of tumor cell. This review summarizes antibody-drug conjugates＇ mechanism of action, classification and the clinical progression of a novel lauched auticancer drug trastuzumab-emtansine（T-DM1, Kadcyla）.

关 键 词：抗体-药物偶联物 曲妥珠单抗-美登木素I(T-DM1) 抗肿瘤药物 靶向治疗 

分 类 号：R979.1[医药卫生—药品]